Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status

Nuvectis Pharma, Inc.

2023-Q3 EPS reported -$1.02

Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.
Net loss $5.9M for Q3 2023, unchanged YoY; R&D expenses $4.5M.
Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer ongoing; preliminary data expected Q1 2024.
NXP900 Phase 1a dose escalation initiated in advanced solid tumors; novel preclinical data presented.
FDA granted NXP800 Orphan Drug Designation for cholangiocarcinoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvectis Pharma, Inc. reported financial results for Third Quarter 2023.

Period: Third Quarter 2023
Result: reported results

Exact text from the filing

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.